AbbVie’s biologic therapy Humira for autoimmune disorders continues to dominate the sales landscape; Gilead’s once-daily hepatitis C treatment Harvoni in 2016 repeated its performance as the world’s second-best-selling prescription medicine.

Johnson & Johnson said a U.S. court had held its patent for autoimmune drug Remicade invalid, ruling in favor of two companies seeking to bring a cheaper version of the blockbuster drug to market.